A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer
NCT02210559
Completed
This is a Phase 1/2 trial to evaluate the safety, tolerability, and efficacy of FG-3019 administered with gemcitabine and nab-paclitaxel in the treatment of locally advanced, unresectable pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/02/2023
Locations: University of California, Los Angeles, Los Angeles, California
Conditions: Pancreatic Cancer (Unresectable)
Register for Updates
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
NCT02041533
Completed
The purpose of this study is to show that Nivolumab will improve progression free survival in subjects with strongly Stage IV or Recurrent PD-L1+ non-small cell lung cancer when compared to chemotherapy
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/02/2023
Locations: Local Institution - 0016, Stanford, California
Conditions: Stage IV or Recurrent Non-Small Cell Lung Cancer
Register for Updates
A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors
NCT05453825
Unknown
This is a study of navicixizumab monotherapy or in combination with paclitaxel or irinotecan in patients with advanced cancer. Patients will be enrolled into one of the following cancer cohorts: * Cohort A: CRC * Cohort B: Gastric and GEJ cancer * Cohort C: TNBC * Cohort D: Platinum-resistant/refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer (ovarian cancer)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2023
Locations: Keck Medicine of USC, Los Angeles, California
Conditions: Colorectal Cancer, Triple Negative Breast Cancer, Gastric Cancer, Ovarian Cancer
Register for Updates
A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer
NCT01647828
Completed
The study consists of a Phase1b lead-in portion to determine the maximum tolerated dose (MTD) of OMP-59R5 in combination with nab-paclitaxel and gemcitabine followed by a Phase 2, multicenter, randomized, placebo-controlled portion to evaluate the efficacy and safety of OMP-59R5 in combination with nab-paclitaxel and gemcitabine in subjects with previously untreated stage IV pancreatic cancer.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
01/19/2023
Locations: CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center, Bakersfield, California +4 locations
Conditions: Stage IV Pancreatic Cancer
Register for Updates
A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)
NCT03398655
Completed
The purpose of this phase 3, randomized, multicenter study is to compare VB-111 and paclitaxel to placebo and paclitaxel in adult patients with Recurrent Platinum-Resistant Ovarian Cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/08/2023
Locations: UCLA-JCCC-Women's Health Clinical Research Unit, Los Angeles, California +5 locations
Conditions: Recurrent Platinum Resistant Ovarian Cancer
Register for Updates
Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
NCT03214250
Completed
The main purposes of this study are to learn how effective the study drug combinations are in treating patients with metastatic pancreatic adenocarcinoma. The drug combinations are APX005M+Nivolumab+Gemcitabine+nab-Paclitaxel, or APX005M+Gemcitabine+nab-Paclitaxel.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/21/2022
Locations: University of California, Los Angeles, Los Angeles, California +2 locations
Conditions: Metastatic Pancreatic Adenocarcinoma
Register for Updates
Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas
NCT03136055
Completed
This is a pilot study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinoma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2022
Locations: University of California, San Francisco, San Francisco, California
Conditions: High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)
Register for Updates
A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread
NCT04132817
Completed
The hypothesis of the CA048-001 Phase 1 clinical trial is targeting multiple mechanisms involved in generating and maintaining antitumor immune response will lead to a tolerable and robust anti-tumor response. This study utilizes an innovative clinical trial design to determine the safety, tolerability, pharmacodynamic activity and efficacy of targeting multiple, distinct combination regimens that modulate several immune and non-immune mechanisms by escalating the number of therapies administere... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/01/2022
Locations: Local Institution, Los Angeles, California +1 locations
Conditions: Breast Cancer
Register for Updates
Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung Cancer
NCT00017407
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. ISIS 3521 may help kill more cancer cells by making tumor cells more sensitive to chemotherapy. It is not yet known if carboplatin and paclitaxel are more effective with or without ISIS 3521. PURPOSE: Randomized phase III trial to compare the effectiveness of carboplatin and paclitaxel with or without ISIS 3521 in treating patients who have stage IIIB or stage IV non-small cel... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
12/01/2022
Locations: ISIS Pharmaceuticals, Inc., Carlsbad, California
Conditions: Lung Cancer
Register for Updates
Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC
NCT02591615
Completed
This is a multicenter randomized phase II to determine if the administration of standard platinum-based chemotherapy before MK-3475 in with Chemotherapy naive stage IV Non-small Cell Lung Cancer (NSCLC) will improve the overall response rate (ORR) compared to MK-3475 administered before chemotherapy. Patients will be given Pembrolizumab as maintenance up to 2 years: Carboplatin and paclitaxel or pemetrexed every 3 weeks x 4 cycles followed by pembrolizumab every 3 weeks for up to 2 years. Pembro... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/28/2022
Locations: UCSD Moores Cancer Center, La Jolla, California
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors
NCT02762981
Completed
The purpose of this study was to assess the safety of the combination of relacorilant (CORT125134), a novel glucocorticoid receptor (GR) antagonist, and nab- paclitaxel in participants with solid tumors and to determine the preliminary efficacy of the combination of relacorilant and nab-paclitaxel. The structure for the study was a single arm, non-randomized, open- label, multicenter trial with no control group.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/09/2022
Locations: 014, San Francisco, California
Conditions: Solid Tumors
Register for Updates
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
NCT01414608
Completed
This randomized phase III trial studies how well giving cisplatin and radiation therapy together with or without carboplatin and paclitaxel works in treating patients with cervical cancer has spread from where it started to nearby tissue or lymph nodes. Drugs used in chemotherapy, such as cisplatin, carboplatin, and paclitaxel, work in different ways to stop the growth of \[cancer/tumor\] cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Exte... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/27/2022
Locations: Sutter Auburn Faith Hospital, Auburn, California +33 locations
Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB Cervical Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7
Register for Updates